TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07105709: A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

Sponsor: GlaxoSmithKline · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 220 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$8,225,600

Rescue Site Savings

+$5,432,000

Unlock Full NCT07105709 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07105709 Rescue Dossier →